Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Renal cell carcinoma, drawn from the whole corpus: 119 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Non-clear-cell histologies understudied.
No validated predictive biomarker for IO.
No predictive biomarker to choose between IO-IO and IO-TKI, or to identify the 20% who achieve durable remission.
Adjuvant therapy treats many who would never relapse; ctDNA shedding is too low for standard MRD approaches.
Background: Neoadjuvant / adjuvant / perioperative. Also on OnCo: Treatment journeys · Survivorship planner.
Favourable-risk disease has no proven OS benefit from any first-line combination.
Non-clear-cell histologies lack dedicated phase 3 evidence.
First-line intensification (triplets) has failed twice; the next step in first line is unclear.
Treatment-free survival and de-escalation after deep response are unstudied prospectively.
Toxicity and dose reductions with lenvatinib-pembrolizumab limit real-world durability.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Small renal mass overtreatment and the absence of a reliable non-invasive diagnostic (CAIX PET awaits approval).
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 67 changes by month →When this page itself was last checked or edited.
Adjuvant clear-cell RCC with pembrolizumab (LITESPARK-022)
Adjuvant RCC with belzutifan (LITESPARK-022)
Adjuvant clear-cell RCC with pembrolizumab
Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC
Active surveillance, partial nephrectomy (usually robotic), or thermal ablation depending on growth, comorbidity, and biopsy; renal mass biopsy increasingly used. (NCCN 2A)